<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Saeed O</submitter><funding>NCATS NIH HHS</funding><funding>NHLBI NIH HHS</funding><funding>National Institutes of Health</funding><pagination>857-864</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC8355019</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>27(8)</volume><pubmed_abstract>&lt;h4>Background&lt;/h4>The safety and effectiveness of oral anticoagulation (OAC) after an ischemic stroke in older patients with heart failure (HF) without atrial fibrillation remains uncertain.&lt;h4>Methods&lt;/h4>Utilizing Get With The Guidelines Stroke national clinical registry data linked to Medicare claims from 2009-2014, we assessed the outcomes of eligible patients with a history of HF who were initiated on OAC during a hospitalization for an acute ischemic stroke. The cumulative incidences of adverse events were calculated using Kaplan-Meier curves and adjusted Cox proportional hazard ratios were compared between patients discharged on or off OAC.&lt;h4>Results&lt;/h4>A total of 8,261 patients from 1,370 sites were discharged alive after an acute ischemic stroke and met eligibility criteria. Of those, 747 (9.0%) were initiated on OAC.  Patients on OAC were younger (77.2±8.0 vs. 80.5±8.9 years, p&lt;0.01). After adjustment for clinical covariates, the likelihood of 1 year mortality was higher in those on OAC (aHR: 1.22, 95% CI 1.05-1.41, p&lt;0.01), while no significant differences were noted for ICH (aHR: 1.34, 95% CI 0.69-2.59, p=0.38) and recurrent ischemic stroke (aHR: 0.78, 95% CI 0.54-1.15, p = 0.21).  The likelihood of all-cause bleeding (aHR: 1.59, 95% CI 1.29-1.96, p&lt;0.01) and all-cause re-hospitalization (aHR: 1.14, 95% CI 1.02-1.27, p = 0.02) was higher for those on OAC.&lt;h4>Conclusion&lt;/h4>Initiation of OAC after an ischemic stroke in older patients with HF in the absence of atrial fibrillation is associated with death, bleeding and re-hospitalization without an associated reduction in recurrent ischemic stroke. If validated, these findings raise caution for prescribing OAC to such patients.</pubmed_abstract><journal>Journal of cardiac failure</journal><pubmed_title>Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation.</pubmed_title><pmcid>PMC8355019</pmcid><funding_grant_id>K23 HL145140</funding_grant_id><funding_grant_id>UL1 TR002556</funding_grant_id><funding_grant_id>UL1 TR001073</funding_grant_id><pubmed_authors>Gupta T</pubmed_authors><pubmed_authors>Bulcha N</pubmed_authors><pubmed_authors>Schwamm LH</pubmed_authors><pubmed_authors>Fonarow GC</pubmed_authors><pubmed_authors>Shah S</pubmed_authors><pubmed_authors>Xian Y</pubmed_authors><pubmed_authors>Saeed O</pubmed_authors><pubmed_authors>Zhang S</pubmed_authors><pubmed_authors>Garcia MJ</pubmed_authors><pubmed_authors>Jorde UP</pubmed_authors><pubmed_authors>Smith EE</pubmed_authors><pubmed_authors>Patel SR</pubmed_authors><pubmed_authors>Matsouaka R</pubmed_authors></additional><is_claimable>false</is_claimable><name>Oral Anticoagulation and Adverse Outcomes after Ischemic Stroke in Heart Failure Patients without Atrial Fibrillation.</name><description>&lt;h4>Background&lt;/h4>The safety and effectiveness of oral anticoagulation (OAC) after an ischemic stroke in older patients with heart failure (HF) without atrial fibrillation remains uncertain.&lt;h4>Methods&lt;/h4>Utilizing Get With The Guidelines Stroke national clinical registry data linked to Medicare claims from 2009-2014, we assessed the outcomes of eligible patients with a history of HF who were initiated on OAC during a hospitalization for an acute ischemic stroke. The cumulative incidences of adverse events were calculated using Kaplan-Meier curves and adjusted Cox proportional hazard ratios were compared between patients discharged on or off OAC.&lt;h4>Results&lt;/h4>A total of 8,261 patients from 1,370 sites were discharged alive after an acute ischemic stroke and met eligibility criteria. Of those, 747 (9.0%) were initiated on OAC.  Patients on OAC were younger (77.2±8.0 vs. 80.5±8.9 years, p&lt;0.01). After adjustment for clinical covariates, the likelihood of 1 year mortality was higher in those on OAC (aHR: 1.22, 95% CI 1.05-1.41, p&lt;0.01), while no significant differences were noted for ICH (aHR: 1.34, 95% CI 0.69-2.59, p=0.38) and recurrent ischemic stroke (aHR: 0.78, 95% CI 0.54-1.15, p = 0.21).  The likelihood of all-cause bleeding (aHR: 1.59, 95% CI 1.29-1.96, p&lt;0.01) and all-cause re-hospitalization (aHR: 1.14, 95% CI 1.02-1.27, p = 0.02) was higher for those on OAC.&lt;h4>Conclusion&lt;/h4>Initiation of OAC after an ischemic stroke in older patients with HF in the absence of atrial fibrillation is associated with death, bleeding and re-hospitalization without an associated reduction in recurrent ischemic stroke. If validated, these findings raise caution for prescribing OAC to such patients.</description><dates><release>2021-01-01T00:00:00Z</release><publication>2021 Aug</publication><modification>2025-04-04T13:57:42.263Z</modification><creation>2025-04-04T13:57:42.263Z</creation></dates><accession>S-EPMC8355019</accession><cross_references><pubmed>33975786</pubmed><doi>10.1016/j.cardfail.2021.02.017</doi></cross_references></HashMap>